|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||34.51 - 34.72|
|52 Week Range||26.35 - 34.98|
|Beta (3Y Monthly)||0.42|
|PE Ratio (TTM)||22.50|
|Forward Dividend & Yield||1.07 (3.27%)|
|1y Target Est||37.90|
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 12) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...
Elisa Mazen, who co-manages the $1.6 billion ClearBridge International Growth fund, isn’t afraid to take a broad definition of growth to find the best opportunities.
OTCQX: RHHBY), today announced positive top line results from the Roche-sponsored Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). The study met the primary endpoint, and demonstrated that Rituxan is superior to MMF in achieving sustained complete remission.
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...
SOUTH SAN FRANCISCO, Calif.-- -- There are currently no FDA approved treatments for children living with granulomatosis with polyangiitis or microscopic polyangiitis The PePRS study is the first global trial of Rituxan in pediatric patients with GPA or MPA Rituxan in combination with glucocorticoids is the only FDA-approved therapy for adults with these two rare forms of vasculitis If approved, this ...
Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.
Swiss drugmaker Roche on Tuesday named a new head of its $13-billion-per-year diagnostics business and also said board member Peter Voser is stepping down to focus on his expanded duties as interim head of Swiss engineering group ABB. Roche's new diagnostics boss, Thomas Schinecker, fills a post that had been led for months on an interim basis by Michael Heuer, who is retiring. Roche's diagnostics unit includes diabetes care, sophisticated laboratory equipment and tests aimed at personalizing cancer treatment.
OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies. Accelerated approval was granted for this indication based on complete response rates observed in a randomised, controlled clinical trial.
OTCQX: RHHBY), today announced positive topline results for NOBILITY, a Phase II clinical trial investigating the safety and efficacy of Gazyva® (obinutuzumab) for adults with proliferative lupus nephritis. The study met its primary endpoint, showing Gazyva, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrated enhanced efficacy compared to placebo plus standard of care alone in achieving complete renal response at one year. In addition, Gazyva met key secondary endpoints showing improved overall renal responses (complete and partial renal response) and serologic markers of disease activity as compared to placebo.
OTCQX: RHHBY) today announced that Peter Voser (61), a member of the Board of Directors of Roche Holding Ltd since 2011, has decided to step down as a member of the Board of Directors of Roche at the end of June 2019 due to his additional role as interim CEO of ABB. Roche Chairman Christoph Franz: "Peter Voser has made important contributions to Roche's success as a member of the Board and the Compensation Committee.
Spark Therapeutics stock tumbled Monday after Swiss biopharma Roche delayed its $4.8 billion takeover of the biotech as regulators in the U.S. and Europe scrutinized the transaction.
The expiration date of Roche's offer has been extended from 5 p.m. Friday, June 14 to 5 p.m. July 31, which suggests Spark shareholders now have until July 31 to tender their shares. Roche has a lot riding on the Spark deal given the pharma giant's recent focus on gene therapies. Spark already has an approved gene therapy, Luxturna, for inherited retinal disease, and more investigational therapies in the pipeline for hemophilia A, hemophilia B, lysosomal storage disorders and neurodegenerative diseases.
The U.S. Food and Drug Administration said Monday it had approved the first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma: A combination of Genentech's Polivy, the chemotherapy bendamustine and a rituximab product. Genentech, a subsidiary of Roche Holding AG , was granted accelerated approval based on the results of a Phase 1b/2 randomized clinical trial that showed that patients on a combination of Polivy (polatuzumab vedotin-piiq), bendamustine and rituximab showed better response rates than those on just bendamustine and rituximab. "Despite meaningful progress in the treatment of diffuse large B-cell lymphoma, treatment options are very limited when the disease is refractory to or recurrent after multiple regimens," Sandra Horning, chief medical officer and head of Global Product Development at Genentech, said in a statement. "Today's approval of this Polivy combination will provide a novel treatment that is both immediately available and very much needed for people with this aggressive disease." Shares of Roche have gained 10.2% in the year to date, while the S&P 500 has gained 15.3%.
The U.S. Food and Drug Administration on Monday granted earlier-than-expected approval to Roche Holding AG's antibody- Polivy for treatment of patients with advanced lymphoma. Polivy was approved in combination with Roche's older drug Rituxan and a chemotherapy agent for adult patients with advanced diffuse large B-cell lymphoma (DLBCL) whose cancer has worsened despite at least two previous lines of therapy. Antibody-drug conjugates are designed to deliver a toxic chemotherapy directly to tumors.
OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies. Accelerated approval was granted for this indication based on complete response rates observed in a randomized, controlled clinical trial.